{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:34:29Z","timestamp":1792784069552,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Zambon SpA"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijantimicag.2017.01.020","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T16:32:17Z","timestamp":1491409937000},"page":"763-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens"],"prefix":"10.1016","volume":"49","author":[{"given":"Maria Lina","family":"Mezzatesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-1972","authenticated-orcid":false,"given":"Giulia","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4457-0737","authenticated-orcid":false,"given":"Gaetano","family":"Maugeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-1823","authenticated-orcid":false,"given":"Tiziana","family":"Zingali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Caio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0015","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ucl.2015.05.005","article-title":"Epidemiology and management of emerging drug-resistant Gram-negative bacteria: extended-spectrum \u03b2-lactamases and beyond","volume":"42","author":"Boyle","year":"2015","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s15010-011-0081-0","article-title":"Klebsiella pneumoniae ESBL producers responsible for severe UTIs in a renal transplant unit","volume":"39","author":"Gona","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0030","series-title":"Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0035","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s40265-013-0143-y","article-title":"Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0040","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jac\/dkt116","article-title":"Emergence of an extensively drug-resistant ArmA- and KPC-2-producing ST101 Klebsiella pneumoniae clone in Italy","volume":"68","author":"Mezzatesta","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/mdr.2008.0765","article-title":"Class I integron-borne blaVIM-1 carbapenemase in a strain of Enterobacter cloacae responsible for a case of fatal pneumonia","volume":"14","author":"Perilli","year":"2008","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijantimicag.2014.04.014","article-title":"Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs","volume":"44","author":"Mezzatesta","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0055","series-title":"Guidelines on urological infections","author":"Grabe","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-015-0095-5","article-title":"Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008","volume":"4","author":"Kahlmeter","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0065","doi-asserted-by":"crossref","first-page":"O633","DOI":"10.1111\/1469-0691.12577","article-title":"In vivo multiclonal transfer of blaKPC-3 from Klebsiella pneumoniae to Escherichia coli in surgery patients","volume":"20","author":"Gona","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0070","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1128\/AAC.00721-09","article-title":"Susceptibility of urinary tract bacteria to fosfomycin","volume":"53","author":"Maraki","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0080","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/cmi.12121","article-title":"VEGF receptor-1 involvement in pericyte loss induced by Escherichia coli in an in vitro model of blood brain barrier","volume":"15","author":"Salmeri","year":"2013","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0085","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/AAC.02614-15","article-title":"Activity of fosfomycin against extended-spectrum-\u03b2-lactamase-producing uropathogens in patients in the community and hospitalized patients","volume":"60","author":"Linsenmeyer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0090","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.50.1.368-370.2006","article-title":"In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures","volume":"50","author":"de Cueto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0100","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijantimicag.2015.09.008","article-title":"In vitro activity of \u2018old antibiotics\u2019 against highly resistant Gram-negative bacteria","volume":"46","author":"Dubourg","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0105","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.01235-09","article-title":"In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and\/or colistin","volume":"54","author":"Endimiani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.020_bib0110","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/AAC.47.9.2850-2858.2003","article-title":"Biological costs and mechanisms of fosfomycin resistance in Escherichia coli","volume":"47","author":"Nilsson","year":"2003","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T19:25:48Z","timestamp":1535916348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0924857917301073"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.020","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}